Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-312: tarlatamab plus durvalumab, carboplatin, and etoposide versus durvalumab plus carboplatin and etoposide as first-line treatment for extensive-stage small cell lung cancer
CTR20252997Phase 3Active
- Sponsor
- Amgen
- Start
- Aug 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tarlatamab, durvalumab, carboplatin, etoposide in small cell lung cancer (SCLC), sponsored by Amgen. Started Aug 2025; status: active.
02
Drugs
tarlatamabdurvalumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20252997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252997.